Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...

The measles rash usually doesn’t appear for more than a week after someone has been exposed. Other symptoms are better early ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

and urticaria pigmentosa mimic urticaria but differ in etiology and treatment. Accurate diagnosis requires distinguishing urticaria from mimickers to guide appropriate treatment strategies and ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Understanding the causes, symptoms, treatment options, and why urticaria may worsen at night is essential for effective management. Urticaria is an inflammatory skin disorder. According to the ...